254 related articles for article (PubMed ID: 24076450)
1. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
2. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S; Nishio S; Okada S; Otsuki T; Fujiwara K; Tanabe H; Takano M; Hasumi Y; Takei Y; Hasegawa T; Matsumoto T; Fujiwara K; Takekuma M; Nakamura K; Shimada M; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2015 Aug; 76(2):335-42. PubMed ID: 26092322
[TBL] [Abstract][Full Text] [Related]
3. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
4. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
5. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
7. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
8. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
9. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
10. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
11. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
12. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
14. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
18. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
20. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]